The goal of this project was to develop a novel gene transfer system based on macrophages (M) as shuttles of recombinant retroviral vectors carrying therapeutic or marker genes. The murine M cell line WGL5 was used as a source of M for this study. We generated retrovirus-producing M by transducing the WGL5 cells with a replication-defective retroviral vector carrying the enhanced green fluorescent protein (EGFP) reporter gene and the Moloney murine leukemia virus (MoMLV) as helper virus. We demonstrated stable integration of the recombinant retrovirus in the M genome, efficient recombinant retrovirus production, and EGFP gene delivery to different cell lines in vitro. To evaluate M-mediated EGFP gene transfer in vivo, allogeneic
Introduction
Central to the application of gene therapy for the treatment of acquired or congenital diseases is the efficient delivery and sustained expression of exogenous genes in cells of target tissues. 1 Several human clinical trials rely on the use of Moloney murine leukemia virus (MoMLV) backbone-based recombinant retroviral vectors to mediate the transfer of therapeutic or marker genes, [2] [3] [4] because they efficiently integrate into the host cell genome thereby ensuring long-term expression of the transgene. 5, 6 At present, the MoMLV-based gene delivery approaches are mainly restricted to ex vivo protocols in which therapeutic genes are transduced into explanted tumor cells, fibroblasts, hematopoietic stem cells, peripheral blood lymphocytes, or tumor-infiltrating lymphocytes (reviewed in Refs 2, 5, 7) . In vivo retrovirusmediated gene transfer is hampered by the high instability of retroviral particles 2 and the difficulties of in vivo targeting the retroviruses to selected tissues. 7 To circumvent these limitations, several approaches have been explored. Fibroblasts producing retroviral vectors carrying the Herpes simplex virus thymidine kinase (HSVtk) suicide gene have been used for the treatment of brain tumors both in animal models and in clinical trials, as a means to enhance the in vivo efficiency of retrovirusmediated gene delivery. [8] [9] [10] The results obtained showed mice were injected s.c. with the retrovirus-producing WGL5 M, that gave rise to solid tumor masses at the injection site, highly infiltrated with host leukocytes. We observed EGFP fluorescence in tumor-infiltrating CD4 + and CD8 + host T lymphocytes, providing direct evidence of the ability of engineered M to mediate EGFP gene delivery to host cells in vivo. Moreover, we showed that retrovirus-producing M could home to different organs in vivo following i.v. injection into mice. These data demonstrate that M can be engineered as cellular vehicles for recombinant retroviruses carrying heterologous genes and suggest potential applications of this novel vector system for gene therapy. Gene Therapy (2001) 8, 431-441. improved gene transfer to neoplastic cells, as compared with the injection of naked retroviruses, 8 but were limited to the site of injection because of the lack of motility of the virus-producing fibroblasts. 9 We have extensively studied the interactions between macrophages (M) and transforming retroviruses to generate immortalized M cell lines, [11] [12] [13] and we were interested in developing M-based vectors capable of efficiently producing and delivering recombinant retroviruses in vivo. M are endowed with biological features that render them worth considering for engineering and are potentially useful in human gene therapy as vehicles of therapeutic genes. They are ubiquitous cells that reside in the vast majority of tissues and accumulate in inflammatory lesions and tumor masses 14 and have been shown to be capable, in certain circumstances, of functioning as reservoirs and vehicles for viral dissemination. 15 Moreover, M are key players in the regulation of cellular immunity against infections and tumors (for a review see , and evidence exists that ex-vivo activated autologous M reinfused into tumor-bearing mice or cancer patients can exert efficient antitumor activity. [20] [21] [22] Both M cell lines and primary M or dendritic cells (DC) have been previously engineered to express tumor-specific antigens or to secrete immunoregulatory cytokines and have been employed in ex vivo experimental protocols of adoptive immunotherapy of cancer. 20, 23, 24 The infection of CD34 + hematopoietic progenitor cells with retroviral vectors followed by in vitro differentiation of transduced cells into mature M or DC has also been carried out as an approach to express stably therapeutic genes in M. [25] [26] [27] However, no attempt has yet been made to explore the possibility of using M as shuttles of infectious retroviral vectors carrying marker or therapeutic genes.
In the present study we have generated retrovirus producer M by double transduction of a well differentiated murine M cell line with the replication-defective retroviral vector pSun1 carrying the enhanced green fluorescent protein (EGFP) reporter gene 28 and MoMLV as helper virus. We demonstrated stable and long-term integration of pSun1 provirus in the genome of M, active constitutive production of the recombinant retroviral vector by engineered M, and efficient in vitro transduction of different types of cells using the M conditioned medium. Finally, we provided direct evidence of the ability of engineered M to transfer the EGFP marker gene to host T lymphocytes in vivo.
Results
Construction of a M cell line expressing the pSun1 retroviral vector carrying the EGFP reporter gene The first goal was to engineer the murine M cell line, WGL5, to express recombinant retroviruses carrying the EGFP reporter gene. The MoMLV-based replicationdefective retroviral vector pBabe 29 was modified to generate the pSun1 construct (Figure 1) , by inserting the fulllength EGFP cDNA downstream to the gag sequence under the control of the LTR promoter. The pSun1 construct, or the empty vector pBabe as a control, were transiently transfected into an ecotropic packaging cell line to produce infectious recombinant retroviruses. We then infected the WGL5 M cell line with the conditioned medium from transfected cells containing a viral titer of 1 × 10 7 CFU/ml. WGL5 M were selected with puromycin and tested for EGFP fluorescence. Flow cytometry analysis of pSun1-transduced M showed intense green fluorescence in 50% of the cells and a two to three log increase in mean fluorescence intensity (MFI) relative to pBabe-transduced cells (Figure 2a) . These results were confirmed by experiments in which fluorescence was measured by direct microscopy, with EGFP signal appearing as a bright and diffuse cytoplasmic and nuclear green fluorescence (Figure 2b ). Both the percentage and the MFI of transduced M remained stable for 6 months of in vitro passaging, suggesting that EGFP did not affect the proliferative activity of the cells. Moreover, Figure 1 EGFP expression did not change the morphology of the M cell line (data not shown). These results demonstrate that the pSun1 recombinant retroviral vector efficiently infected the WGL5 M cell line yielding intense and long-term EGFP cellular fluorescence.
The transduced WGL5 M bulk culture was cloned by the limiting dilution technique, and EGFP fluorescence was measured by flow cytometry in 270 clonal isolates to identify the clone with the highest level of viral expression. Molecular and flow cytometric analysis were carried out on a selection of five clonal isolates representative of the entire fluorescent fraction of clones. Retroviral mRNA expression was evaluated by Northern blot analysis with the EGFP cDNA. As shown in Figure 3a (lanes 2-6), pSun1 transcript appeared as a 3.7 kb band of unspliced genomic RNA without subgenomic species, consistent with the reported inactivation of the splice donor site in the original pBabe vector. 29 The EGFP probe did not crossreact with any cellular or viral mRNA (Figure 3a, lane 1) , indicating the specificity of the hybridization. pSun1 expression levels varied substantially from clone to clone (lanes 2-6). Although slight mRNA fluctuations were detectable within each clone in three independent determinations, maximal expression was consistently displayed by clone 111. Accordingly, clone 111 exhibited the highest level of EGFP fluorescence (Figure 3b ). To determine the pattern of provirus integration, the DNA from the selected clones was digested with the restriction enzyme BamHI, which cuts once in the provirus upstream to the EGFP gene, and analyzed by Southern blot. Various integration patterns were detected in the different clones (Figure 3c ). The presence of multiple bands suggests the random integration of the provirus and the existence of a variable number of integrated proviral copies. The specificity of the hybridization is shown by the lack of signal in control cells (CTR).
These results demonstrate that the pSun1 provirus was stably integrated in the genome of the M clones, which Generation of MIRO M cell line producing high titers of pSun1 retrovirus Experiments were carried out to convert WGL5-EGFP M into a retrovirus-producing cell line. The pSun1 provirus was rescued by cell superinfection with MoMLV. WGL5-EGFP M were co-cultured for 48 h with mitomycin C-treated MoMLV producer fibroblasts, generating the WGL5-EGFPinf bulk culture. To evaluate pSun1 retrovirus production from WGL5-EGFPinf, we infected NIH 3T3 fibroblasts with the M supernatant and measured EGFP expression by FACS analysis (Figure 4a , left panel). The percentage of EGFP-positive NIH 3T3 cells was taken as a measure of retroviral transduction efficiency. Up to 45% of fibroblasts displayed bright green fluorescence with a peak 10 times higher than that of mock-transduced cells, indicating that WGL5-EGFPinf produced pSun1 retrovirus with an infection efficiency of about 45%.
To obtain a homogeneous M cell line producing a high retroviral titer, we cloned WGL5-EGFPinf by limiting dilution and evaluated the ability of over 300 clones to transfer the EGFP reporter gene into NIH 3T3 fibroblasts. The clone with the highest transduction efficiency, hereafter referred to as MIRO, transferred the reporter gene into more than 90% of cells (Figure 4a , right panel) and produced a viral titer ranging from 4 to 8 × 10 7 CFU/ml in different determinations, that was stable for over 6 months. As shown in Figure 4b , EGFP fluorescence pattern in infected fibroblasts was similar to that detected in M (Figure 2b) .
Next, we wished to investigate MIRO range of infection as compared with that of fibroblasts similarly engineered to produce pSun1 recombinant retrovirus and used as a control. The TS/A mammary adenocarcinoma, the Neuro 2A neuroblastoma, the CE-2 fibrosarcoma murine tumor cell lines and NIH 3T3 fibroblasts were incubated with the supernatants from either virus-producing MIRO or producer fibroblasts and tested by FACS for EGFP fluorescence. As depicted in Figure 5 , infection with MIRO-derived conditioned medium resulted in gene transfer efficiencies of 15, 60, 35 and 97% depending on the cell lines. Comparable percentages of infected cells were achieved when conditioned medium from pSun1-producing fibroblasts was used, suggesting that retrovirus transduction efficiency was dependent upon the target, and not the retrovirus producer, cell type.
These results demonstrate that we were successful in engineering a M cell line to produce a high titer of recombinant retrovirus carrying the EGFP reporter gene and that genetically modified M were capable of transferring the transgene into different types of cells in vitro.
MIRO M-mediated EGFP gene delivery to host T cells in vivo
The critical question was whether MIRO could deliver the EGFP reporter gene to host cells in vivo. To address this issue, we exploited the tumorigenic potential of WGL5 M that can give rise to solid tumors in mice. Allogeneic recipient DBA-2 mice, differing from WGL5 M in the major histocompatibility complex antigens (H-2), were used for these experiments, because they pro- . Solid growing tumors heavily infiltrated with host leukocytes became evident at the injection site 5-7 days after cell injection, regressing within 25-30 days (data not shown). Mice were killed 2 weeks after challenge, and tumor-derived single cell suspensions were analyzed by flow cytometry for EGFP fluorescence, H-2 antigens, and cell lineage-specific markers. Cells recovered from MIRO or WGL5-EGFP-injected mice displayed intense green fluorescence, whereas no background autofluorescence was detectable in tumor cells from mice that received wild-type WGL5 M (data not shown), indicating the in vivo stability of EGFP fluorescence and the high sensitivity of this reporter gene for the detection of genetically modified cells in vivo. To discriminate injected M from host leukocytes, cell suspensions were labeled with phycoerythrin-conjugated anti-H-2 d or anti-H-2 b mAbs (red fluorescence), and EGFP green fluorescence was then assessed in the H-2 d+ cell population. Of the cells injected 75 ± 8% were M because they were positive for the H-2 b alloantigens, whereas 25 ± 3.5% were host tumor-infiltrating cells because they were positive for the H- 
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To characterize the EGFP + host leukocytes, single cell suspensions from MIRO tumors were labeled with phycoerythrin-conjugated mAbs specific for T (anti-CD4, anti-CD8), B (anti-B220) or NK (anti-NK) cell lineage antigens and analyzed for both red (lineage markers) and green (EGFP) fluorescence. Seventy-eight per cent of the host cell infiltrate were T lymphocytes, that comprised both CD4 + (48%) and CD8 + (30%) cells, 4% were B lymphocytes and 7% were NK cells (Table 1) . Among infiltrating leukocytes, only T cells were positive for EGFP ( Table 1 ). The analysis of the proportion of transduced CD4
+ and CD8 + lymphocytes is depicted in Figure 6b and Table 1 . Both CD4 + and CD8 + T cell populations were susceptible to viral transduction, although we consistently observed a preferential infection of CD8 + cells. In fact, relative to the total number of CD4 + and CD8 + lymphocytes present in the tumor infiltrate, 4.9 and 11.2%, respectively, expressed EGFP green fluorescence (Figure 6b, lower panel) , that represented the 2.6% and the 3.7%, respectively, of the total number of host tumorinfiltrating leukocytes (Table 1 ). In contrast, no EGFP + T lymphocytes were detected in control tumors (Figure 6b , middle and upper panels).
In conclusion, we demonstrated that MIRO M transduced the EGFP reporter gene into host T lymphocytes in vivo, indicating that cells of the M lineage could potentially function as cellular vehicles for in vivo gene delivery.
In vivo homing of MIRO M
To establish the homing of engineered M into mouse tissues, we examined the localization of MIRO M following injection into the tail vein of DBA/2 mice. Six groups of mice were injected i.v. with 3 ϫ 10 7 cells and killed at various intervals after injection. Different organs were harvested and examined for the presence of fluorescent M. Table 2 shows the time-course of MIRO M distribution into the blood, spleen, lungs, liver and brain of injected mice. At 15 min after injection, EGFP-positive M were found mainly in the peripheral blood and in the lungs, and few cells were already present in the spleen increasing by 30 min. By 1 h after injection, fluorescent M were detectable in the liver and started to decrease in the blood, whereas at 5 h they completely disappeared from the circulation and were found primarily in the spleen and lungs. By 24 h after injection, MIRO M were predominantly located in the liver and spleen, and a few cells were detectable in the brain. A similar pattern of cell distribution was observed in every mouse per group. Figure 7 shows a representative cryosection of spleen harvested 24 h after MIRO M injection. Bright green fluorescent M are clearly evident throughout the spleen follicular areas.
These data demonstrate the ability of MIRO M to home into different organs in vivo following i.v. injection.
Discussion
In this study, we explored a novel experimental approach for the in vivo transfer of exogenous genes based on M as vehicles of recombinant retroviruses. We engineered the WGL5 M cell line to produce the pSun1 retroviral vector carrying the EGFP reporter gene under the control of the viral LTR, and we provided direct evidence that engineered M could efficiently deliver the reporter gene to different types of cells in vitro and in vivo. The WGL5-M cell line expressing high levels of pSun1 virus was established by retroviral infection, because this procedure increases the efficiency of gene integration and reduces the possibility of integrated DNA deletion as compared with plasmid transfection (for a review see Ref. 30 ). pSun1 provirus was stably integrated in the cell genome, and transduced M expressed high levels of EGFP fluorescence. EGFP provides a convenient tag for assessing in vitro and in vivo gene transduction, as its expression can be readily detected in live cells and tissues by flow cytometry or fluorescent microscopy by virtue of its intrinsic fluorescence. 28 The EGFP toxicity reported by other investigators 31 was not observed. Tranduced or untransduced M had the same growth characteristics, and we did not detect any attenuation of EGFP expression over a period of 6 months (data not shown), as opposed to that which occurred in other systems. Upon superinfection of engineered M with MoMLV, we obtained the MIRO M cell line yielding 4 to 8 × 10 7 CFU/ml of EGFP-expressing retroviruses, a titer higher than that reported in the literature for other retrovirusproducing systems. 30, 34 We demonstrated MIROmediated retroviral gene transduction into a panel of cell lines in vitro with an efficiency ranging from 97% to 15% depending on the target cell type. Because retrovirus infectivity is strictly receptor dependent, 35 the variability in gene transfer efficiency was probably due to a differential expression of retroviral receptors on the cell surface. It is noteworthy that MIRO M were as efficient at transducing the different cell lines as control pSun1-producing NIH-3T3 fibroblasts, thus confirming the conclusion that the efficiency of infection was dependent on the targetand not the retrovirus-producing cell type.
32,33
The ability of MIRO M to mediate retroviral gene transfer was also demonstrated in vivo in a mouse model. For this purpose, we developed a system in which we could easily distinguish host cells, MIRO M, EGFP-positive and -negative cells and in which host cells were actively proliferating and, thus, susceptible to retroviral infection. 36 We took advantage of the fact that MIRO M (H-2 b ), similarly to other transformed M cell lines, 37 can proliferate in vivo in an allogeneic host (DBA/2 mice, H-2 d ) giving rise to a highly immunogenic tumor which is eventually rejected by infiltrating host leukocytes. This model provides a precise way to distinguish transplanted M from host cells using the H-2 antigens as markers and it has all the characteristics needed to detect in vivo gene transfer from retrovirus-producing M to host leukocytes. We detected 6.3% of H-2 d+ host leukocytes infiltrating MIRO-derived tumors expressing intense EGFP fluorescence, whereas none of the host cells infiltrating control tumors was EGFP
+ . We could demonstrate EGFP expression only in T lymphocytes, that were the predominant cell type within the tumor infiltrate. However, a low percentage of other cell types below the detection limit of FACS analysis might have also been transduced. Both CD4 + and CD8 + subpopulations were susceptible to pSun1 infection, although a preferential transduction of CD8 + lymphocytes was observed. These findings suggest that a higher percentage of CD8 + , than CD4 + , cells reacted and proliferated in response to the H-2 alloantigens on MIRO M, in agreement with the observation that the allogeneic immune responses are mainly mediated by CD8 + lymphocytes. 38 Collectively, these observations provide direct evidence of the ability of MIRO M to deliver the EGFP reporter gene to host T cells in vivo. These results are consistent with our previous study showing that M producing the oncogenic J2 retrovirus were able to mediate retrovirus infection of host T lymphocytes when injected s.c. into allogeneic mice. 37 However, the read out of that system was the growth of host-derived lymphomas due to lymphocyte infection with the J2 virus, whereas the system reported here allows the measurement of the actual percentage of infected cells.
Retroviral vector producer cells (VPCs) have been preGene Therapy viously used for in vivo delivery of therapeutic or marker genes into localized malignancies. Experimental approaches based on the intracerebral injection of fibroblasts producing recombinant retroviruses carrying the HSVtk suicide gene were developed for the treatment of malignant gliomas 8, 9, 39, 40 and leptomeningeal neoplasias, 41 both in animal models and in humans, and a similar strategy was attempted for hepatoma gene therapy in a rat model. 42 Because these studies were designed primarily to evaluate the potential antitumor efficacy of in situ gene delivery, the actual percentage of infected cells was not measured, although both HSVtk expression and tumor growth inhibition were observed. Successful transduction of proliferating tumor or endothelial cells with reporter genes was demonstrated following VPCs injection into proliferating brain tumors 10, 39 or s.c. coinjection of VPCs with tumor cell lines. 8, 43 Gene transfer efficiency was estimated in one study to range from 10 to 70%. 39 Because the level of retrovirus infection correlates with the degree of cell proliferation, 36 the differences in transduction efficiency among various experimental systems may be due to the frequency of dividing cells available for retroviral integration and expression. In our model, only a small fraction of host alloreactive leukocytes is proliferating at the tumor site in response to the allogeneic stimulation. 38 Thus, the level of gene transduction that we have achieved in vivo is significant because it represents the infection of the majority of replicating host T lymphocytes. A comparable gene transfer efficiency (4.3-12%) was detected by Fassati et al 44 in muscle satellite cells after injection of lacZ-carrying VPCs into regenerating skeletal muscles. The biological significance of our results is suggested by the fact that transduced T lymphocytes can undergo further proliferation and clonal expansion, thereby amplifying the number of cells expressing the transgene. These considerations are based on the logical assumption that alloreactive T lymphocytes were the cells transduced, but this point deserves formal evaluation.
Studies on the homing capabilities of endogenous and adoptively transferred monocyte/macrophages have shown that these cells have a natural capacity of migrating and infiltrating most tissues of the body [45] [46] [47] and that they can rapidly accumulate to sites of inflammation and to solid primary or metastatic tumors following systemic administration, both in mice and humans. 45, 48 Here, we demonstrate that engineered M cell lines can efficiently extravasate and localize into various organs after injection into the tail vein of DBA/2 mice with a homing distribution pattern similar to that reported for fresh, ex vivo differentiated M or dendritic cells. [45] [46] [47] After an initial arrest in the lungs, MIRO M rapidly migrated to other tissues, primarily liver and spleen, with minimal or no retention in the blood. These findings provide experimental evidence of the migratory capability of retrovirusproducing M cell lines and enable the identification of potential target organs for M-mediated gene transfer.
In conclusion, our data demonstrate the technical feasibility of engineering cells of the M lineage for retroviral gene transfer in vivo in a murine model and suggest the potential applicability of this novel vector system for gene therapy. The preclinical testing for the adaptation of this approach to the human situation will require the development of additional systems such as the engineering of ex vivo isolated peripheral blood monocytes or
CD34
+ bone marrow-derived M to produce therapeutic retroviruses and their subsequent reinfusion into the host to deliver the therapeutic gene.
Materials and methods

Cell lines and culture conditions
The WGL5 murine M cell line was derived in our laboratory from an hystiosarcoma spontaneously arising in Sencar mice. The ecotropic packaging cell line Phoenix, expressing gag, pol and env genes from the MoMLV and kindly provided by Dr GP Nolan (Stanford University, CA, USA), was derived from the human embrionic kidney cell line 293T transformed with adenovirus E1a and carrying a temperature-sensitive T antigen co-selected with neomicin. 34 The neuroblastoma cell line of A strain origin, Neuro 2A, was obtained from the American Tissue Culture Collection (ATCC, Rockville, MD, USA); the mammary adenocarcinoma cell line, TS/A, was established by P Nanni (IST, Milan, Italy) from the first in vivo transplant of a moderately differentiated mammary adenocarcinoma spontaneously arising in a 20-month-old female BALB/cnACr mouse. CE-2 cell line was derived from a poorly immunogenic methylcholantrene-induced sarcoma of Balb/c mice by Dr G Parmiani (IST, Milan, Italy). MoMLV producer cell line, SNU19, kindly provided by Dr J Pierce (NIH, Bethesda, MD, USA), was derived from NIH 3T3 fibroblasts infected with wild-type MoMLV. The WGL5, Phoenix and Neuro 2A cell lines were cultured in D-MEM (ICN Biomedicals, Aurora, OH, USA) supplemented with 10% heat-inactivated FCS (Hyclone Laboratories, Logan, UT, USA), 2 mm l-glutamine (BioWhittaker, Walkersville, MD, USA), 100 U/ml penicillin and 100 g/ml streptomycin (BioWhittaker), referred to here as complete medium. The TS/A and CE-2 cell lines were cultured in RPMI-1640 (ICN Biomedical) supplemented as described above. The NIH 3T3 cells and MoMLV producer fibroblasts were grown in D-MEM supplemented with 10% calf serum (BioWhittaker), 2 mm l-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Cell lines were maintained at 37°C in a humidified incubator containing 20% O 2 , 5% CO 2 and 75% N 2 . The content of endotoxin in all reagents was below the detection limit of 6 pg/ml, as determined by the chromogenic Limulus amebocyte lysate test (QCL-1000; BioWhittaker).
Retroviral vector
The MoMLV-derived retroviral vector pBabe, 29 kindly provided by Dr H Land (Imperial Cancer Research Fund, London, UK), was used as a backbone for the construction of the pSun1 recombinant retroviral vector (Figure 1) . Briefly, the pBabe vector contains the fulllength LTRs, the extended packaging site, and retains an adjacent gag sequence to enhance the efficiency of viral incapsidation, thus increasing the steady state levels of genomic vector RNA. 29 A mutation in the 5′-end gag startcodon prevents translation of the gag product. A polilinker for insertion of exogenous genes was placed downstream to the gag sequence. An inactivated splice donor site avoids possible recombination due to the activation of cryptic splice acceptor sites within the inserted cDNA. This vector expresses the puromycin resistance gene under control of an internal SV40 promoter, as a selectable marker for selection of infected cells.
The recombinant retroviral construct pSun1 was generated by inserting the enhanced green fluorescent protein (EGFP) full-length cDNA into the poli-linker of the pBabe plasmid backbone. EGFP gene encodes a red-shifted variant of the Aequora Victoria green fluorescent protein that has been optimized for brighter fluorescence and higher expression in mammalian cells. 28 The EGFP cDNA was excised from the pEGFP-N1 plasmid (Clontech, Palo Alto, CA, USA) as a KpnI/XbaI fragment and subcloned into the pUC18 vector (MBI Fermentas, Vilnius, Lithuania). It was then excised by digestion with the restriction enzymes EcoRI/SalI and subcloned within the polilinker of pBabe, under the LTR promoter control. All cloning orientations were confirmed by restriction digests. The cloned EGFP cDNA is expressed as an unspliced viral mRNA of 3.7 kb.
Transfection of the Phoenix packaging cell line pSun1 or pBabe vector, as a negative control, were transiently transfected into the Phoenix packaging cells by using the calcium phosphate precipitation method. Briefly, a total of 10 g of plasmid DNA in 500 l CaCl 2 × H 2 O (124 mm CaCl 2 ) was mixed with 500 l of 2× HBS (280 mm NaCl, 1.5 mm Na 2 HPO 4 × 2H 2 O, 50 mm Hepes) with constant bubbling. This solution was then added to 30 × 10 6 cells plated on to 100-mm plates (Costar, Cambridge, MA, USA) in complete medium with addition of 25 m chloroquine (Sigma, St Louis, MO, USA) to inhibit lysosomal DNAses. Eight hours after transfection, medium was replaced, and 48 h later viruscontaining supernatants were recovered, centrifuged at 500 g for 10 min, filtered through a 0.45-m filter (Millipore, Bedford, MA, USA) to remove cell debris, and used to infect macrophages. Viral titers in the supernatants were higher than 10 7 /ml, as measured by the clonogenic assay described below.
Clonogenic assay Viral titers were determined by infection of NIH-3T3 cells according to standard clonogenic assay procedure with puromycin selection. 30 Briefly, 5 × 10 5 NIH 3T3 fibroblasts were plated on to a 6-cm Petri dish in complete medium the day before infection, as described above. After infection with different dilutions of filtered supernatants from semiconfluent virus-producing cells in the presence of 8 g/ml polybrene, target fibroblasts were cultured at 37°C for 48 h before being transferred to 10-cm dishes and selected with 1 g/ml puromycin. Selection medium was changed after each period of 2-3 days, and 10-14 days later colonies were stained with Giemsa solution and counted.
Infection of the WGL5 M cell line M infection with the Phoenix-conditioned medium was performed when M were in the log phase of growth. Briefly, WGL5 cell line was plated on to six-well Costar plates at 5 × 10 5 cells per well in 2 ml of retrovirus-conditioned medium for 5 h, in the presence of 7 g/ml of polybrene (Sigma) to promote virus-binding to the cell surface. Infected cells were then washed three times with fresh medium to remove free retroviral particles and then cultured for an additional 2 days in complete medium. Puromycin-resistant cells were selected by addition of 10 g/ml puromycin (ICN Biomedicals, Costa Mesa, CA, USA) to the culture medium. Stable transfectants were cloned by the limiting dilution technique.
Generation of retrovirus-producer M M superinfection was performed by cocultivation with MoMLV producer SNU19 fibroblasts. SNU19 cells were plated on to 60-mm Costar plates at 1 × 10 5 cells per well and treated with 10 g/ml Mitomycin C (ICN Biomedicals) for 3 h to stop cell proliferation though allowing virus production. SNU19 cells were then washed and plated in 4 ml of fresh medium. After 24 h, half of the medium was replaced with new medium containing M at the final concentration of 2.5 × 10 5 cells/ml, and 7 g/ml of polybrene was added. Cell coculture was carried out for 48 h. M were removed by washing the producer monolayer with complete medium, cloned, and tested for virus production by supernatant titration on 3T3 cells, as described below.
To obtain pSun1 virus producer fibroblasts, MoMLV producer SNU19 cells were transfected with the pSun1 construct by calcium phosphate precipitation protocol, and cells were tested for virus production by supernatant titration on 3T3 cells, as described below.
Assessment of in vitro retrovirus production
To examine production of retroviral particles, 5 × 10 5 pSun1 producer M or fibroblasts/ml were plated on to 100-mm dishes and culture supernatants used 2 days later to infect NIH 3T3, CE-2, Neuro 2A or TS/A cells plated the day before transduction into six-well plates over glass cover slips at a density (7.5 × 10 4 cells per well) that resulted in 40-60% of confluence on the day of infection. Target cells were infected in the presence of 7 g/ml polybrene, as described above. After 5 h of culture, conditioned medium was replaced with fresh medium and target cells were cultured for 48h before analysis for EGFP expression was carried out.
In vivo M injection and tissue harvest Eight-week-old normal, female, DBA/2 (H-2 d ) were obtained from Charles River Laboratories, Calco, Italy. Three animals per group were used for each experiment. A few groups of mice were injected s.c in the left inguinal flank with 0.2 ml of a single cell suspension containing 1 × 10 7 MIRO, WGL5-EGFP or WGL5 M cells. Mice were killed 2 weeks after challenge, and subcutaneously grown tumors were excised and minced with the Medimachine (Dako, Glostrup, Denmark) to obtain single cell suspensions. Other groups of mice were injected into the tail vein with 3 × 10 7 MIRO cells/0.5 ml using a 1-ml syringe with a 27-gauge needle and killed at selected times after challenge. Whole blood samples were collected by orbital bleeding, depleted of red cells by standard lysis procedure, and cell suspensions were processed as described below. Spleen, lungs, liver and brain were removed, fixed ON in freshly prepared PBS/paraformaldehyde 4% at 4°C, embedded in OCT Compound (Tissue-Tek, Elkhart, IN, USA), and snap-frozen in isopentane chilled with liquid nitrogen. Six-micrometer tissue sections were cut using a cryostat and placed on to Polysine glass slides (BDH Laboratory Supplies, Milan, Italy).
Analysis of EGFP expression by direct fluorescence microscopy and quantification of in vivo gene transfer In vitro cultured M and blood samples were washed twice in PBS (BioWhittaker), fixed with freshly prepared PBS/paraformaldehyde 4% at 4°C for 30 min, and washed again with PBS. Cells (1 × 10 4 ) were applied to Polysine glass slides by centrifuging at 900 r.p.m. for 10 min, using a cytocentrifuge (Shandon, Cheshire, UK). The slide preparations were mounted in PBS/glycerol 50% and examined for the presence of EGFP fluorescence under a Zeiss Axiovert 135 microscope (Zeiss, Jena, Germany) equipped with a 450-490 nm long-pass excitation filter, 510 nm dichroic reflector, and a 520-750 nm long-pass emission filter. Adherent cells were cultured directly on to glass microscope slides and then analyzed. Cryostat sections were also observed for the presence of EGFP fluorescence by direct fluorescence microscopy, as described above. Quantitative studies of the cytospin preparations or the cryostat section for the presence of EGFP + cells were performed in a blind fashion on three or more samples from distinct mice per group by evaluating 10 randomly chosen fields in each sample. Cells were counted under a microscope at a magnification of ×40 (objective) and ×10 (ocular lens). Photomicrographs were taken with a Zeiss camera.
Flow cytometric analysis
In vitro cultured M or single cell suspensions derived from tumors were washed twice with PBS and resuspended to 1 × 10 7 cell/ml in PBS containing 2% FCS and 0.05% NaN 3 . All mAbs staining procedures were carried out at 4°C. One hundred microlitres of each cell suspension were preincubated for 30 min with the anti-mouse CD16/CD32 rat mAb, purchased from PharMingen (San Diego, CA, USA, USA) to block Fc␥ III/II receptors nonspecific staining. The following R-phycoerythrin-conjugated mAbs were then added to the cell suspensions: anti-H-2b and H-2d mouse mAbs, provided by PharMingen; anti-mouse CD4, CD8, B220 and NK rat mAbs, obtained from Cederline, Ontario, Canada. After a second 30 min incubation, cells were washed twice and analyzed by flow cytometry subjected to flow cytometric analysis with a FACScan (FACScan, Becton Dickinson, San Jose, CA, USA) using excitation at 588 nm and fluorescence detection at 530 ± 30 nm (for EGFP) or 575 ± 26 nm (for phycoerythrin). Propidium iodide (PI; Sigma) was added to all samples before analysis to allow identification and elimination of dead cells from the analysis. Positive staining was determined by comparison with control cells stained with appropriate isotypematched control mAbs purchased from PharMingen.
Southern and Northern blot analysis
To analyze the genomic integration pattern of pSun1 in M, genomic DNA was isolated from 30 × 10 6 cells using the DNAzol reagent (Life Technologies), according to the manufacturer's instructions. Ten micrograms of genomic DNA from each sample were digested with BamHI restriction enzyme, which cuts once in the provirus upstream to the EGFP gene. Digested DNA was separated on a 0.6% agarose gel, denatured by a treatment with a solution of NaOH 0.4 n/NaCl 0.6 m, transferred on to Nytran membranes (Schleicher & Schuell, Keen, NH, USA) and crosslinked by UV radiation.
Total cellular RNA was purified from 30 × 10 6 M using the TriZOL RNA reagent (Life Technologies, Milan, Italy), according to the manufacturer's instructions. Twenty micrograms of total RNA from each sample were electrophoresed under denaturing conditions on a 1.2% agarose gel containing 2.2 m formaldehyde, transferred to Nytran membranes and crosslinked by UV radiation.
Filters were prehybridized for 4 h at 42°C in Hybrisol solution (Oncor, Gaithersburg, MD, USA) and hybridized at 42°C overnight with 2 × 10 6 c.p.m./ml of 32 P (5′-␣ 32 PdCTP, 3000 Ci/mmol; Amersham, Arlington Heights, IL, USA) random-primed (Life Technologies)-labeled probes. Membranes were then washed and autoradiographed using Kodak XAR-5 (Kodak, New York, USA) film and intensifying screens at −80°C as previously described. 49 The EGFP and the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Clontech), cDNAs were used as probes.
